PRISM BioLab was granted a new patent covering a novel class of bicyclic PepMetics® compounds on September 30, 2025. For more details, please click here (Japanese language PDF).

We would like to announce that PRISM BioLab and Servier have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please click here (English language PDF).

We would like to announce that PRISM BioLab and Eli Lilly and Company have mutually agreed to terminate the collaboration and licensing agreement previously established between the two companies. For more details, please see the full announcement below: https://contents.xj-storage.jp/xcontents/AS09340/e4067309/8794/4b19/8225/2fb73b3fca54/140120250728521212.pdf

PRISM BioLab is pleased to announce that we obtained a patent for our novel compound library on May 30th, 2025. For more details, please click here (Japanese language PDF).

TOKYO, Japan, 23 May 2025: — PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386, created through collaboration research with Eisai Co., Ltd. , and Lenvatinib mesylate (“lenvatinib”) will be presented by...

CEO Dai Takehara will participate in the “103rd IR Seminar for Individual Investors” hosted by Logmi Finance on Saturday, May 17, 2025. As a company committed to sustainable growth and corporate value enhancement, we actively promote dialogue with shareholders and investors through our proactive IR activities. We will continue our efforts to communicate information and...

Nikkei Biotech has published an interview with our CEO Dai Takehara, and our Director/Head of R&D Dr. Park. Special Feature: Peptide Drug Discovery Finally Taking Off “The Future of PPI Drug Discovery: A Conversation with PRISM BioLab CEO Dai Takehara” https://bio.nikkeibp.co.jp/atcl/news/p1/25/04/15/13203/

PRISM BioLab has been featured in The Nikkei (Nihon Keizai Shimbun). “PRISM BioLab and AI Drug Discovery Startup Partner for Efficient Drug Development” https://www.nikkei.com/article/DGXZQOUC1173U0R10C25A4000000/

TOKYO, Japan, 14 April 2025 — PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a drug discovery collaboration with Elix, Inc., effective April 1, 2025. This partnership will accelerate research on these challenging molecular targets by...